LMRI — Lumexa Imaging Holdings Inc
NASDAQ · Health Care · Health Care
- Latest Close
- $9.32
- 30-Day Move
- -49.7%
- Market Cap
- $884M
- Shares Outstanding
- 94,570,000
- P/B Ratio
- 2.83
- ROE
- -8.0%
Analyst consensus: Buy · 14 analysts
Lumexa Imaging Holdings Inc
A read-only Alphactor snapshot forLumexa Imaging Holdings Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$9.32
30-Day Move
-49.7%
Market Cap
$884M
Shares Outstanding
94,570,000
P/B Ratio
2.83
ROE
-8.0%
$9.32
-49.7%last 90 delayed daily bars
90D High
$19.45
90D Low
$7.23
Avg Volume
889,149
Gross margin is running at 15.4%, which gives a quick read on operating quality before you open the full model.
Net margin is -4.6%, useful for comparing LMRI against peers in Health Care.
LMRI is down 49.7% over the last 30 trading days shown on this page.
Latest operating income is $-7M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$44.54
Rule of 40
7.2%
Dark Pool Short %
71.0%
Latest Close
$9.32
30-Day Move
-49.7%
Market Cap
$884M
Shares Outstanding
94,570,000
P/B Ratio
2.83
ROE
-8.0%
ROA
-2.7%
Gross Margin
15.4%
Operating Margin
8.3%
Net Margin
-4.6%
Debt / Equity
1.5
Current Ratio
1.27
Latest Revenue
$268M
Revenue
$268M
Gross Profit
$42M
Operating Income
$-7M
Net Income
$-29M
Gross Margin
1540.0%
Net Margin
-460.0%
Current Ratio
1.27
Debt / Equity
1.50
Fair Value
$44.54
Upside / Downside
+377.9%
Signal
Undervalued
Implied Growth
31.5%
EV/Rev
$44.54
Growth Assumption
4.6%
Discount Rate
10.1%
Terminal Growth
2.0%
Base FCF
$17M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
0.61
Distress
Piotroski
7
Strong (7-9)
Cash Conversion
-0.36x
Rule of 40
7.2%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2023-12-31 | $936M | $-13M | $-122M | $14M |
| 2024-12-31 | $949M | $-16M | $-94M | $13M |
| 2025-12-31 | $1.0B | $27M | $-47M | $-6M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-02-25 | Walker James Edward Jr. | A | 12,414 | $0.00 |
| 2025-12-12 | Martin James Anthony | A | 27,027 | $0.00 |
| 2025-12-12 | Martin James Anthony | A | 27,027 | $0.00 |
| 2025-12-12 | Walker James Edward Jr. | A | 4,932 | $0.00 |
| 2025-12-12 | Stewart Russell | A | 4,232 | $0.00 |
| 2025-12-12 | Stewart Russell | A | 4,232 | $0.00 |
| 2025-12-12 | Szeker Julie | M | 1,250,000 | $0.00 |
| 2025-12-12 | Szeker Julie | A | 81,081 | $0.00 |
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| JANUS INVESTMENT FUND-Janus Henderson Triton Fund | 1,033,387 | 0.01% | 2025-12-31 |
| T. Rowe Price Small-Cap Stock Fund, Inc. | 894,890 | 0.01% | 2025-12-31 |
| AB CAP FUND, INC.-AB Small Cap Growth Portfolio | 857,864 | 0.01% | 2026-02-28 |
| AB DISCOVERY GROWTH FUND, INC. | 704,767 | 0.01% | 2026-02-28 |
| AIM Growth Series -Invesco Main Street Small Cap Fd. | 629,335 | 0.01% | 2025-12-31 |
| JANUS INVESTMENT FUND-Janus Henderson Venture Fund | 598,213 | 0.01% | 2025-12-31 |
| T. Rowe Price Eqy. Fd.s, Inc.-T. Rowe Price Inst. Small-Cap Stock Fd. | 486,258 | 0.01% | 2025-12-31 |
| Vanguard Explorer Fund | 490,018 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Invesco
Filed 2026-02-19
$27M
--
Goldman Sachs
Filed 2026-02-10
$19M
--
Citadel Advisors
Filed 2026-02-17
$16M
--
FMR LLC (Fidelity)
Filed 2026-02-17
$13M
--
Vanguard Group
Filed 2026-01-29
$4M
--
D.E. Shaw
Filed 2026-02-17
$4M
--
Marshall Wace
Filed 2026-02-13
$3M
--
Geode Capital Management
Filed 2026-02-09
$2M
--
4.36
Consensus
Buy—
—
—
14
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.